Chugai Pharmaceutical Co., Ltd.
General ticker "CHGCF" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $77.8B (TTM average)
Chugai Pharmaceutical Co., Ltd. does not follow the US Stock Market performance with the rate: -2.3%.
Estimated limits based on current volatility of 2.0%: low 52.17$, high 54.30$
Factors to consider:
- Company pays dividends (annually): last record date 2025-06-30, amount 0.87$ (Y1.59%)
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [30.23$, 51.60$]
- 2025-12-31 to 2026-12-31 estimated range: [28.18$, 49.11$]
Financial Metrics affecting the CHGCF estimates:
- Negative: with PPE of 28.3 at the end of fiscal year the price was very high
- Positive: Operating profit margin, % of 46.30 > 18.64
- Positive: Return on assets ratio (scaled to [-100,100]) of 14.92 > 6.04
- Positive: Industry earnings per price (median), % of 5.67 > 4.43
- Negative: Investing cash flow per share per price, % of -2.05 <= -0.66
- Positive: 5.52 < Industry operating cash flow per share per price (median), % of 8.11
- Positive: 0.33 < Operating cash flow per share per price, % of 4.03
Short-term CHGCF quotes
Long-term CHGCF plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | ¥1,259,946.00MM | ¥1,111,367.00MM | ¥1,170,611.00MM |
| Operating Expenses | ¥726,637.00MM | ¥672,193.00MM | ¥628,609.00MM |
| Operating Income | ¥533,309.00MM | ¥439,174.00MM | ¥542,002.00MM |
| Non-Operating Income | ¥-2,143.00MM | ¥4,647.00MM | ¥1,032.00MM |
| Interest Expense | ¥61.00MM | ¥0.00MM | ¥0.00MM |
| R&D Expense | ¥149,626.00MM | ¥174,868.00MM | ¥181,440.00MM |
| Income(Loss) | ¥531,166.00MM | ¥443,821.00MM | ¥543,034.00MM |
| Taxes | ¥156,737.00MM | ¥118,349.00MM | ¥155,717.00MM |
| Profit(Loss)* | ¥172,983.00MM | ¥325,472.00MM | ¥185,088.00MM |
| Stockholders Equity | ¥1,424,387.00MM | ¥1,625,580.00MM | ¥1,901,499.00MM |
| Inventory | ¥292,206.00MM | ¥273,480.00MM | ¥240,067.00MM |
| Assets | ¥1,869,758.00MM | ¥1,932,547.00MM | ¥2,208,373.00MM |
| Operating Cash Flow | ¥244,112.00MM | ¥409,925.00MM | ¥447,600.00MM |
| Capital expenditure | ¥71,239.00MM | ¥74,258.00MM | ¥54,899.00MM |
| Investing Cash Flow | ¥-145,994.00MM | ¥-37,290.00MM | ¥-227,365.00MM |
| Financing Cash Flow | ¥-145,641.00MM | ¥-139,331.00MM | ¥-141,006.00MM |
| Earnings Per Share** | ¥105.17 | ¥197.80 | ¥112.47 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.